COVID-19 ПАНДЕМИЯСЫ КЕЗІНДЕ ЖҮЙЕЛІ ҚЫЗЫЛ ЖЕГІМЕН НАУҚАСТАРДЫ ЕМДЕУ ЖӘНЕ МОНИТОРИНГ ЖҮРГІЗУ БОЙЫНША ТӘЖІРИБЕЛІК НҰСҚАУЛАР
##semicolon##
https://doi.org/10.31082/1728-452X-2020-213-214-3-4-53-58##semicolon##
жүйелі қызыл жегі##common.commaListSeparator## COVID-19##common.commaListSeparator## емдеу##article.abstract##
COVID-19 коронавирустық инфекциясының клиникалық көріністері жүйелі қызыл жегі (ЖҚЖ) ауруына ұқсас болады. Бұл мақалада осы екі аурудың салыстырмалы диагностикасы көрсетілген. Сонымен қатар коронавирусты инфекция пандемиясы кезінде белсенділігі әртүрлі ЖҚЖ науқастарды жүргізу бойынша дәрігерлерге тәжірибелік нұсқаулар берілген.
##submission.citations##
Nassonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiia. [Rheumatology. Clinical guidelines]. Moscow: GEOTAR Media; 2017. 464 p.
World Health Organization Coronavirus disease 2019 (COVID-19) situation report 48, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4
Gross O, Moerer O, Weber M, Huber T, Scheithauer S. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020 16-22 Маy;395(10236):e87-e88. DOI: 10.1016/S0140-6736(20)31041-2
Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression. Therapy, a Case Report. Iran J Kidney Dis. 2020 May;14(3):239-242
Dhital R, Pandey RK, Poudel DR, Oladunjoye O, Paudel P, Karmacharya P. All-cause hospitalizations and mortality in systemic lupus erythematosus in the US: Results from a national inpatient database. Rheumatol Int. 2020;40(3):393-7
Solovyev SK, Aseeva EA, Popkova TV, et al. Systemic lupus erythematosus: new horizons for diagnosisand therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(1):5-14. (Im Russ.). DOI: 10.14412/1995-4484-2020-5-14
Sawalha AH, Manzi S. Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020. DOI: 10.5152/eurjrheum.2020.20055
Wallace DJ. Antimalarial drugs in the treatment of rheumatic diseases, 2020. Available from: https://www. uptodate. com/ contents/ antimalarial drugs in the treatmentof rheumatic- disease? search= hydroxychloroquine& source= search_ result& selectedTitle= 2~ 148& usage_ type= default& display_ rank= 1# H7
Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol. 2018 May;30(3):249–55. DOI: 10.1097/BOR.0000000000000500.
Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral in-fections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7. DOI: 10.1016/s1473-3099(03)00806-5
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. DOI: 10.1016/j.ijantimicag.2020.105949
Kim A HJ, Sparks JA, Liew JW, et al. A Rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hy-droxychloroquine for COVID-19. Ann Intern Med. 2020 March 30:M20-1223. DOI: 10.7326/M20-1223
Mok CC. The Jakinibs in systemic lupus erythematosus: progress and pro-spects. Expert Opin Investig Drugs. 2019;28(1):85-92. DOI: 10.1080/13543784.2019.1551358
Psarras A, Emery P. Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. DOI: 10.1093/rheumatology/kew431
Muskardin T LW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214-28. DOI: 10.1038/nrrheum.2018.31
You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019 Oct;78(10):1441-1443. DOI: 10.1136/annrheumdis-2019-215455
Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. DOI: 10.1016/S0140-6736(18)31363-1
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31. DOI: 10.1016/S0140-6736(20)30304-4
Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32. DOI: 10.1007/s40259-019-00333-w
Williams B, Zhang Yi. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. Lancet. 2020 30 May-5 June;395(10238):1671-1673. DOI: 10.1016/S0140-6736(20)31131-4
Wan Yu, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-e00128. DOI: 10.1128/JVI.00127-20
Gurwitz D. Angiotensin receptor blockers as tentative SARS-COV-2 therapeutics. Drug Dev Res. 2020;81(5):537-540. DOI: 10.1002/ddr.21656
Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Science & Medicine. 2020;7:e000396. DOI: 10.1136/lupus-2020-000396
Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020 Jun;79(6):837-839. DOI: 10.1136/annrheumdis-2020-217566
##submission.downloads##
##submissions.published##
##issue.issue##
##section.section##
##submission.license##
##submission.copyrightStatement##
##submission.license.cc.by4.footer##
